InMed Pharmaceuticals (NASDAQ:INM) Posts Earnings Results

InMed Pharmaceuticals (NASDAQ:INM) announced its earnings results on Wednesday. The company reported ($3.64) earnings per share (EPS) for the quarter, Zacks reports. InMed Pharmaceuticals had a negative return on equity of 65.74% and a negative net margin of 137.41%.

InMed Pharmaceuticals Price Performance

Shares of INM traded up $0.04 during midday trading on Friday, reaching $3.14. The stock had a trading volume of 13,436 shares, compared to its average volume of 958,455. The company has a current ratio of 5.07, a quick ratio of 4.22 and a debt-to-equity ratio of 0.08. The company has a market capitalization of $2.26 million, a price-to-earnings ratio of -0.23 and a beta of 0.19. The company’s 50-day moving average is $4.30 and its 200 day moving average is $4.71. InMed Pharmaceuticals has a 12-month low of $2.41 and a 12-month high of $15.70.

About InMed Pharmaceuticals

InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry.